title: Protecting the kidney from complement: atypical haemolytic uraemic syndrome.
abstract: Atypical haemolytic uraemic syndrome is a thrombotic microangiopathy with a predominant renal phenotype. Research developments in the last 15 years have led to the elucidation of the role of complement over activation in the pathogenesis of the disease. This was to lead to the successful introduction of targeted pharmacological therapy, in the form of the complement inhibitor, eculizumab.
authors.affiliation: Renal Services Centre, Freeman Hospital, Newcastle-upon-Tyne, UK.
authors.forename: Vicky
authors.initials: V
authors.lastname: Brocklebank
authors.affiliation: The Institute of Genetic Medicine, Newcastle University, Newcastle-upon-Tyne, UK david.kavanagh@ncl.ac.uk.
authors.forename: David
authors.initials: D
authors.lastname: Kavanagh
mesh_terms: D061067:Antibodies, Monoclonal, Humanized; D065766:Atypical Hemolytic Uremic Syndrome; D003169:Complement Inactivator Proteins; D003165:Complement System Proteins / Q000502:physiology*; D006801:Humans; D007668:Kidney / Q000503:physiopathology*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D003169:Complement Inactivator Proteins; D003165:Complement System Proteins; C481642:eculizumab
keywords: Haemolytic uraemic syndrome; acute kidney injury; complement; transplantation